Nightstar Therapeutics plc (“
Nightstar”) is
pleased to announce an update to the expected timetable of events
relating to the scheme of arrangement (the
“
Scheme”) pursuant to which Tungsten Bidco
Limited, a newly-incorporated company and wholly-owned indirect
subsidiary of Biogen Inc., will acquire the entire issued and to be
issued share capital of Nightstar.
The Scheme remains subject to certain conditions
including sanction by the Court at the Court Hearing, which will
now take place on 5 June 2019 (as opposed to 6 June 2019 as
previously announced), and the delivery of a copy of the Court
Order to the Registrar of Companies. Subject to the Scheme
receiving the sanction of the Court and the delivery of a copy of
the Court Order to the Registrar of Companies, the Scheme is still
expected to become effective on 7 June 2019.
The expected timetable of principal events for
the implementation of the Scheme is set out below.
Unless otherwise defined herein, capitalised
terms and expressions used in this announcement shall have the
meanings given to them in the Scheme Document.
|
|
Event |
Expected time and / or date |
|
|
Latest Time for Nightstar ADS Holders to cancel out of the
Nightstar ADS Programme and receive Nightstar Shares ahead of the
Scheme Record Time |
4.59 p.m. (New York time) on 31 May 2019 |
|
|
Court Hearing to sanction the Scheme |
5 June 2019 |
|
|
Last day of trading in Nightstar ADSs on Nasdaq |
6 June 2019 |
|
|
Scheme Record Time |
6.00 p.m. (London time) on 6 June 2019 |
|
|
Effective Date of the Scheme |
7 June 2019 |
|
|
Despatch of cheques and crediting of CREST for Consideration due
under the Scheme |
as soon as practicable after the Effective Date (and in any event
within 14 days of the Effective Date) |
|
|
Cancellation of listing of Nightstar ADSs on Nasdaq |
17 June 2019 |
|
|
Enquiries:
Nightstar
Investor Information |
investors@nightstartx.com |
|
|
Media Enquiries |
media@nightstartx.com |
|
|
Information |
info@nightstartx.com |
|
|
Centerview Partners (Financial adviser
to Nightstar)
Alan
Hartman |
+1 212 380
2665 |
|
|
Andrew Rymer |
+1 212 429 2349 |
|
|
James Hartop |
+44 (0)20 7409 9730 |
|
|
Finsbury (PR adviser to
Nightstar)
Kal Goldberg |
+1 646 805 2005 |
|
|
Chris Ryall |
+1 646 306 0747 |
|
|
Abigail Farr |
+1 646 805 2090 |
|
|
Important notices relating to financial
advisers
Centerview Partners UK LLP ("Centerview
Partners"), which is authorised and regulated by the FCA,
is acting exclusively for Nightstar and no one else in connection
with the matters referred to in this announcement. Centerview
Partners is not and will not be responsible to anyone other than
Nightstar for providing the protections afforded to its clients or
for providing advice in connection with the contents of this
announcement or any matter referred to in this announcement.
The City Code on Takeovers and
Mergers
The City Code on Takeovers and Mergers does not
apply to the Acquisition.
Overseas shareholders
The release, publication or distribution of this
announcement in jurisdictions other than the United Kingdom and the
United States may be restricted by law and therefore any persons
who are subject to the laws of any jurisdiction other than the
United Kingdom or the United States (including Restricted
Jurisdictions) should inform themselves about, and observe, any
applicable legal or regulatory requirements. Any failure to comply
with applicable legal or regulatory requirements of any
jurisdiction may constitute a violation of securities laws in that
jurisdiction. This announcement has been prepared for the purpose
of complying with English law and the information disclosed may not
be the same as that which would have been disclosed if this
announcement had been prepared in accordance with the laws of
jurisdictions outside England.
Copies of this announcement and any formal
documentation relating to the Acquisition are not being, and must
not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in or into or from any Restricted Jurisdiction
or any jurisdiction where to do so would constitute a violation of
the laws of such jurisdiction and persons receiving such documents
(including custodians, nominees and trustees) must not mail or
otherwise forward, distribute or send them in or into or from any
Restricted Jurisdiction. Doing so may render invalid any related
purported vote in respect of acceptance of the Acquisition.
If the Acquisition is implemented by way of an
Offer, the Offer may not (unless otherwise permitted by applicable
law and regulation) be made, directly or indirectly, in or into or
by use of the mails or any other means or instrumentality
(including, without limitation, facsimile, e-mail or other
electronic transmission, telex or telephone) of interstate or
foreign commerce of, or any facility of a national, state or other
securities exchange of any Restricted Jurisdiction and the
Acquisition will not be capable of acceptance by any such use,
means, instrumentality or facilities or from within any Restricted
Jurisdiction.
Further details in relation to Nightstar
Shareholders in overseas jurisdictions are contained in the Scheme
Document.
Notice to U.S. investors in
Nightstar
The Acquisition relates to the shares of a U.K.
company and is being made by means of a scheme of arrangement
provided for under Part 26 of the Companies Act 2006 and subject to
the proxy solicitation rules under the U.S. Exchange Act. The
Acquisition, implemented by way of a scheme of arrangement, is not
subject to the tender offer rules under the U.S. Exchange Act. If,
in the future, Bidder exercises its right to implement the
Acquisition by way of an Offer, subject to the terms of the
Implementation Agreement, the Acquisition will be made in
compliance with applicable U.S. laws and regulations.
It may be difficult for U.S. Nightstar
Shareholders and Nightstar ADS Holders to enforce their rights and
any claim arising out of the U.S. federal securities laws, because
Nightstar is located in a non-U.S. country, and some or all of its
officers and directors are residents of a non-U.S. country. U.S.
Nightstar Shareholders and Nightstar ADS Holders may not be able to
sue a non-U.S. company or its officers or directors in a non-U.S.
court for violations of the U.S. securities laws. Further, it may
be difficult to compel a non-U.S. company and its affiliates to
subject themselves to a U.S. court's judgment.
U.S. Nightstar Shareholders and Nightstar ADS
Holders are urged to consult with legal, tax and financial advisers
in connection with making a decision regarding the Acquisition.
Warning Concerning Forward-Looking
Statements
All statements included in this announcement,
other than statements or characterisations of historical fact, are
forward-looking statements within the meaning of the federal
securities laws, including Section 21E of the U.S. Exchange Act,
and other securities laws. Whenever Nightstar uses words such as
"believe", "expect", "anticipate", "intend", "plan", "estimate",
"will", "may", "predict", "could", "seek", "forecast" and negatives
or derivatives of these or similar expressions, they are making
forward-looking statements. Examples of such forward-looking
statements include, but are not limited to, references to the
anticipated benefits of the Acquisition and the expected time of
effectiveness of the Acquisition. These forward-looking statements
are based upon Nightstar's present intent, beliefs or expectations,
but forward-looking statements are not guaranteed to occur and may
not occur.
Nightstar Shareholders are cautioned that any
forward-looking statements are not guarantees of future performance
and may involve significant risks and uncertainties, and that
actual results may vary materially from those in the
forward-looking statements. Important risk factors that may cause
Nightstar's actual results to differ materially from their
forward-looking statements include, but are not limited to: (1) the
Acquisition is subject to the satisfaction or waiver of certain
conditions, including the sanction of the Scheme by the Court,
which conditions may not be satisfied or waived; (2) uncertainties
as to the timing of the consummation of the Acquisition and the
ability of each party to consummate the Acquisition; (3) the risk
that the Acquisition disrupts the parties' current operations or
affects their ability to retain or recruit key employees; (4) the
possible diversion of management time on Acquisition-related
issues; (5) litigation relating to the Acquisition; (6) unexpected
costs, charges or expenses resulting from the Acquisition; and (7)
potential adverse reactions or changes to business relationships
resulting from the announcement or completion of the
Acquisition.
The information contained in Nightstar's filings
with SEC, including in Nightstar's Form 10-K, as amended by Form
10-K/A, for the year ended 31 December 2018, identifies other
important factors that could cause actual results to differ
materially from those stated in or implied by the forward-looking
statements in this announcement. Nightstar's filings with the SEC
are available on the SEC's website at www.sec.gov. You should not
place undue reliance upon forward-looking statements. Except as
required by law, Nightstar does not intend to update or change any
forward-looking statements as a result of new information, future
events or otherwise.
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Mar 2025 to Apr 2025
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2024 to Apr 2025